Search

Your search keyword '"Hardebeck, Molly Catherine"' showing total 13 results
Start Over Author "Hardebeck, Molly Catherine"
13 results on '"Hardebeck, Molly Catherine"'

2. Supplementary Figure 3 from Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma

Author

Gil del Alcazar, Carlos Rodrigo, primary, Hardebeck, Molly Catherine, primary, Mukherjee, Bipasha, primary, Tomimatsu, Nozomi, primary, Gao, Xiaohuan, primary, Yan, Jingsheng, primary, Xie, Xian-Jin, primary, Bachoo, Robert, primary, Li, Li, primary, Habib, Amyn A., primary, and Burma, Sandeep, primary

Published
2023
Full Text
View/download PDF

3. Supplementary Figure 1 from Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma

Author

Gil del Alcazar, Carlos Rodrigo, primary, Hardebeck, Molly Catherine, primary, Mukherjee, Bipasha, primary, Tomimatsu, Nozomi, primary, Gao, Xiaohuan, primary, Yan, Jingsheng, primary, Xie, Xian-Jin, primary, Bachoo, Robert, primary, Li, Li, primary, Habib, Amyn A., primary, and Burma, Sandeep, primary

Published
2023
Full Text
View/download PDF

4. Supplementary Figure 4 from Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma

Author

Gil del Alcazar, Carlos Rodrigo, primary, Hardebeck, Molly Catherine, primary, Mukherjee, Bipasha, primary, Tomimatsu, Nozomi, primary, Gao, Xiaohuan, primary, Yan, Jingsheng, primary, Xie, Xian-Jin, primary, Bachoo, Robert, primary, Li, Li, primary, Habib, Amyn A., primary, and Burma, Sandeep, primary

Published
2023
Full Text
View/download PDF

5. Supplementary Figure 5 from Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma

Author

Gil del Alcazar, Carlos Rodrigo, primary, Hardebeck, Molly Catherine, primary, Mukherjee, Bipasha, primary, Tomimatsu, Nozomi, primary, Gao, Xiaohuan, primary, Yan, Jingsheng, primary, Xie, Xian-Jin, primary, Bachoo, Robert, primary, Li, Li, primary, Habib, Amyn A., primary, and Burma, Sandeep, primary

Published
2023
Full Text
View/download PDF

6. Supplementary Figure 2 from Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma

Author

Gil del Alcazar, Carlos Rodrigo, primary, Hardebeck, Molly Catherine, primary, Mukherjee, Bipasha, primary, Tomimatsu, Nozomi, primary, Gao, Xiaohuan, primary, Yan, Jingsheng, primary, Xie, Xian-Jin, primary, Bachoo, Robert, primary, Li, Li, primary, Habib, Amyn A., primary, and Burma, Sandeep, primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figure Legend from Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma

Author

Gil del Alcazar, Carlos Rodrigo, primary, Hardebeck, Molly Catherine, primary, Mukherjee, Bipasha, primary, Tomimatsu, Nozomi, primary, Gao, Xiaohuan, primary, Yan, Jingsheng, primary, Xie, Xian-Jin, primary, Bachoo, Robert, primary, Li, Li, primary, Habib, Amyn A., primary, and Burma, Sandeep, primary

Published
2023
Full Text
View/download PDF

8. A phase Ib study of xentuzumab plus abemaciclib and fulvestrant in patients (pts) with advanced hormone receptor-positive (HR+), HER2-negative breast cancer (BC) with visceral or non-visceral disease.

Author

Yee, Douglas, primary, LoRusso, Patricia, additional, Sablin, Marie Paule, additional, Prat, Aleix, additional, Stradella, Agostina, additional, Utriainen, Meri, additional, Oliveira, Mafalda, additional, Yonemori, Kan, additional, Naito, Yoichi, additional, Hardebeck, Molly Catherine, additional, Puig, Marta, additional, Hu, Joy, additional, Biyukov, Tsvetan Nikolov, additional, and Iwata, Hiroji, additional

Published
2021
Full Text
View/download PDF

9. Abstract CT165: An open label, multi-cohort, phase Ib study of xentuzumab and abemaciclib: Preliminary results from the advanced non-small cell lung cancer (NSCLC) cohort

Author

LoRusso, Patricia, primary, García-Corbacho, Javier, additional, Braiteh, Fadi S., additional, Gonçalves, Anthony, additional, Ricci, Francesco, additional, Iwata, Hiroji, additional, Capelán, Marta, additional, Sablin, Marie Paule, additional, Prat, Aleix, additional, Hardebeck, Molly Catherine, additional, Puig, Marta, additional, Huang, Dennis Chin-Lun, additional, Hsu, Mingchi, additional, and Yee, Douglas, additional

Published
2020
Full Text
View/download PDF

10. Abstract P3-11-05: A phase Ib multi-cohort study of xentuzumab and abemaciclib in patients (pts) with solid tumors and breast cancer (BC) - Initial report of four dose-finding cohorts

Author

Yee, Douglas, primary, Oliveira, Mafalda, additional, Iwata, Hiroji, additional, Gonçalves, Anthony, additional, García-Corbacho, Javier, additional, Sablin, Marie Paule, additional, Prat, Aleix, additional, Hardebeck, Molly Catherine, additional, Puig, Marta, additional, Huang, Dennis Chin-Lun, additional, Hsu, Mingchi, additional, and LoRusso, Patricia, additional

Published
2020
Full Text
View/download PDF

11. Abstract P1-19-09: Updated subgroup tumor response of abemaciclib plus aromatase inhibitor for hormone receptor positive (HR+), HER2 negative advanced breast cancer (MONARCH 3)

Author

O’Shaughnessy, Joyce, primary, Johnston, Stephen, additional, Martin, Miguel, additional, Huober, Jens, additional, Toi, Masakazu, additional, Andre, Valerie AnneMarie, additional, Martin, Holly Rene, additional, Hardebeck, Molly Catherine, additional, Di Leo, Angelo, additional, and Goetz, Matthew Philip, additional

Published
2020
Full Text
View/download PDF

12. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

Author

Johnston, Stephen Rd D S., Martin, Miguel, Di Leo, A., Im, Seock–Ah –A, Awada, Ahmad, Forrester, Tammy, Frenzel, Martin, Hardebeck, Molly Catherine, Cox, Joanne, Barriga, Susana, Toi, Masakazu, Iwata, Hiroji, Goetz, Matthew M.P., Johnston, Stephen Rd D S., Martin, Miguel, Di Leo, A., Im, Seock–Ah –A, Awada, Ahmad, Forrester, Tammy, Frenzel, Martin, Hardebeck, Molly Catherine, Cox, Joanne, Barriga, Susana, Toi, Masakazu, Iwata, Hiroji, and Goetz, Matthew M.P.

Abstract

At the MONARCH 3 interim analysis, abemaciclib plus a nonsteroidal aromatase inhibitor (AI) significantly improved progression-free survival (PFS) and objective response rate (ORR) with a tolerable safety profile as initial treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC). MONARCH 3 is a randomized, phase III, double-blind study of abemaciclib/placebo (150 mg twice daily, continuous) plus nonsteroidal AI (1 mg anastrozole or 2.5 mg letrozole, daily). A total of 493 postmenopausal women with HR+, HER2− ABC with no prior systemic therapy in this setting were enrolled. The primary endpoint was investigator-assessed PFS (final analysis after 240 events); other endpoints included response and safety evaluations. Here we analyze the final PFS data and update secondary endpoints. The abemaciclib arm had a significantly longer median PFS than the placebo arm (28.18 versus 14.76 months; hazard ratio [95% confidence interval], 0.540 [0.418–0.698]; p =.000002). The ORR was 61.0% in the abemaciclib arm versus 45.5% in the placebo arm (measurable disease, p =.003). The median duration of response was longer in the abemaciclib arm (27.39 months) compared to the placebo arm (17.46 months). The safety profile was consistent with previous reports. The most frequent grade ≥ 3 adverse events in the abemaciclib versus placebo arms were neutropenia (23.9% versus 1.2%), diarrhea (9.5% versus 1.2%), and leukopenia (8.6% versus 0.6%). Abemaciclib plus a nonsteroidal AI was an effective initial treatment with an acceptable safety profile for HR+, HER2− ABC., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2019

13. Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma

Author

Gil del Alcazar, Carlos Rodrigo, primary, Hardebeck, Molly Catherine, additional, Mukherjee, Bipasha, additional, Tomimatsu, Nozomi, additional, Gao, Xiaohuan, additional, Yan, Jingsheng, additional, Xie, Xian-Jin, additional, Bachoo, Robert, additional, Li, Li, additional, Habib, Amyn A., additional, and Burma, Sandeep, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results